Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Design Therapeutics (Nasdaq: DSGN), a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in two major investor conferences. The company will present at the 2024 Jefferies London Healthcare Conference on November 19, 2024, at 10:00 a.m. GMT in London, and participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 11:30 a.m. ET in New York. Live webcasts will be available on the company's website and archived for at least 30 days after the presentations.
Design Therapeutics (Nasdaq: DSGN), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di trattamenti per gravi malattie genetiche degenerative, ha annunciato la sua partecipazione a due importanti conferenze per investitori. L'azienda presenterà al 2024 Jefferies London Healthcare Conference il 19 novembre 2024, alle 10:00 GMT a Londra, e parteciperà a una chat informale al Piper Sandler 36th Annual Healthcare Conference il 3 dicembre 2024, alle 11:30 ET a New York. Le dirette web saranno disponibili sul sito web dell'azienda e archiviate per almeno 30 giorni dopo le presentazioni.
Design Therapeutics (Nasdaq: DSGN), una empresa de biotecnología en etapa clínica centrada en el desarrollo de tratamientos para graves enfermedades genéticas degenerativas, ha anunciado su participación en dos importantes conferencias para inversores. La empresa presentará en la 2024 Jefferies London Healthcare Conference el 19 de noviembre de 2024, a las 10:00 GMT en Londres, y participará en una charla informal en la Piper Sandler 36th Annual Healthcare Conference el 3 de diciembre de 2024, a las 11:30 ET en Nueva York. Se realizarán webcasts en vivo disponibles en el sitio web de la empresa y archivados durante al menos 30 días después de las presentaciones.
디자인 테라퓨틱스(Nasdaq: DSGN)는 심각한 퇴행성 유전 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, 두 개의 주요 투자자 회의에 참가한다고 발표했습니다. 이 회사는 2024년 11월 19일 오전 10:00 GMT에 런던에서 열리는 2024 Jefferies London Healthcare Conference에 발표할 예정이며, 2024년 12월 3일 오전 11:30 ET에 뉴욕에서 열리는 Piper Sandler 36th Annual Healthcare Conference에서 대화 형식의 세션에 참여합니다. 생중계 웹캐스트는 회사 웹사이트에서 제공되며 프레젠테이션 후 최소 30일 동안 아카이브됩니다.
Design Therapeutics (Nasdaq: DSGN), une entreprise de biotechnologie en phase clinique axée sur le développement de traitements pour des maladies génétiques dégénératives graves, a annoncé sa participation à deux grandes conférences d'investisseurs. L'entreprise présentera à la 2024 Jefferies London Healthcare Conference le 19 novembre 2024 à 10h00 GMT à Londres et participera à un échange informel lors du Piper Sandler 36th Annual Healthcare Conference le 3 décembre 2024 à 11h30 ET à New York. Des webcasts en direct seront disponibles sur le site Web de l'entreprise et archivés pendant au moins 30 jours après les présentations.
Design Therapeutics (Nasdaq: DSGN), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien für schwere degenerative genetische Erkrankungen konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 19. November 2024 um 10:00 GMT auf der 2024 Jefferies London Healthcare Conference in London präsentieren und an einem informellen Gespräch auf der Piper Sandler 36th Annual Healthcare Conference am 3. Dezember 2024 um 11:30 ET in New York teilnehmen. Live-Übertragungen werden auf der Website des Unternehmens verfügbar sein und mindestens 30 Tage nach den Präsentationen archiviert werden.
- None.
- None.
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
2024 Jefferies London Healthcare Conference
Presentation: Tuesday, November 19, 2024, at 10:00 a.m. GMT
Location: London, UK
Piper Sandler 36th Annual Healthcare Conference
Fireside Chat: Tuesday, December 3, 2024, at 11:30 a.m. ET
Location: New York, NY
Live webcasts of the presentations will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) presenting at the Jefferies London Healthcare Conference 2024?
When is Design Therapeutics (DSGN) participating in the Piper Sandler Healthcare Conference 2024?
How long will Design Therapeutics (DSGN) conference webcasts be available?
What type of company is Design Therapeutics (DSGN)?
